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Background: Cigarette smoking is the major risk factor for chronic obstructive pulmonary disease (COPD). But a
fewer smoking cessation measures were conducted in communities for smokers with COPD in China. The aim of
our study was to assess the preventive effects of behavioral interventions for smoking cessation and potential
impact factors in smokers with COPD in China.
Methods: In a randomised controlled smoking cessation trial 3562 patients with COPD who were current smoker
were allocated to intervention group received behavioral intervention and control group received the usual care for
two years. The primary efficacy endpoint was the complete and continuous abstinence from smoking from the
beginning of month 24 to the end of month 30. Participants were followed up at month 48.
Results: Continuous smoking abstinence rates from month 24 to 30 were significantly higher in participants
receiving behavioral intervention than in those receiving usual care (46.4% vs 3.4%, p < 0.001). Continuous
abstinence rates from months 24 to 36 (45.8% vs 4.0%) and months 24 to 48 (44.3% vs 5.1%) were also higher in
participants receiving behavioral intervention than in those control group. Family members or family physicians/
nurses smoking were first identified to influence smoking cessation.
Conclusions: Behavioral intervention doubled the smoking cessation rate in patients with COPD and was complied
well by the general practitioners. The family members and family physicians/nurses smoking were the main risk
factors for smoking cessation.
Trial registration: Chinese Clinical Trials Registration (ChiCTR-TRC-12001958).
Keywords: Chronic obstructive pulmonary disease, Smoker, Behavioral intervention, Smoking cessation, Risk factorsBackground
Chronic obstructive pulmonary disease (COPD) is a
progressive systemic inflammatory disease that is usu-
ally an abnormal response to noxious particles and
gases (more often, tobacco smoke) in susceptible indi-
viduals. Cigarette smoking is a worldwide risk factor
for COPD [1,2], which accounts for 80-90% of COPD
patients [3]. Løkke and colleagues found that smoking
significantly increased the cumulative incidence of
COPD in a 25 year follow up study [4]. The highest* Correspondence: loupeian2004@yahoo.com.cn
1The Xuzhou Center for Disease Control and Prevention, 142 West Erhuan
Road, Xuzhou City, Jiangsu Province, People's Republic of China 221006
Full list of author information is available at the end of the article
© 2013 Lou et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orincidence for all stages of COPD was 35.5% that oc-
curred in continuous smokers, while the incidence of
never smokers was only 7.8% [4]. Comparing cigarette
smoking status in COPD patients, Zhou et al. found
that the greater amount of smoking, the deeper inha-
lation into the airway and start smoking at earlier age
had the greater risks of COPD [5]. Kanner et al. investi-
gated mild stage of COPD patients continuously smo-
king, the speed of forced expiratory volume in 1 second
(FEV1) was declined when suffered from the lower
airflow illness. Stopping smoking protected these people
with mild COPD from this additional loss of lung
function [6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prevent lung function deterioration for COPD patients.
A longitudinal cohort study showed that continuous
smokers had a much steep decline of lung function than
those stopped smoking, while never smokers had the best
lung function [7]. Lung Health Study confirmed that
smoking cessation could reduce smoking-related decline
in lung function [8,9]. When COPD patients with severely
impaired lung function stopped smoking, their lung func-
tion might be not recovered, but the subsequent decline
tend to be normal [10,11]. On the other hand, smoking
cessation also improved airway hyperresponsiveness for
COPD patients [12]. Smoking cessation at the early stage
was able to benefit COPD prognosis [7,8,11,13], which
was more effective than stop smoking at the later stagesAnalysed (n=1,377)
Excluded from analysis:
Not complete exhaled carbon monoxide 
(CO) level test (n=11); 
Incomplete data (n=15)
14 healthcare
Lost to follow-up (unable to contact: n=20)
Discontinued intervention (died: n=370)
1,814 were allocated in 7 healthcare centers
Received allocated intervention (n=1,793)
Refused to participate: n=21.
Behavioral  intervention
7 healthcare centers
Figure 1 Consort figure of the trial profile.[14]. These data suggested the importance of COPD
patients quit smoke as early as possible [5].
In China, over 40 million people suffered from COPD,
and more than 1.28 million died from it every year [15].
About 80-90% of patients with COPD were smokers [16].
Although efficacious smoking cessation methods have
been established for patients with COPD [17-19], no more
stringent advice or pharmacological therapies have been
applied for COPD patients to quit smoking compared
with general smokers [20], and examined the influencing
factors of community-based smoking cessation trial in
current smokers with COPD in China especially.
In present study, we conducted a randomized controlled
trial to assess the efficacy of a two-year course of beha-
vioral interventions on helping patients with COPD to quitAnalysed (n=1,230) 
Excluded from analysis:




Lost to follow-up (unable to contact: n=26)
Discontinued intervention (died: n=457)
1,748 were allocated in seven communities
Received allocated intervention (n=1,730)
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The study was a randomized controlled trial conducted
form from January 2008 to May 2012, which involves
three months patients’ recruitment, two years’ interven-
tion, two years’ monitoring. Recruitment of practices took
place in 28 communities based on our previous epidemio-
logical study [21]. Fourteen healthcare centers enrolled in
the study; General healthcare centers in the intervention
group received support to implement the behavioral in-
tervention program, whereas the control healthcare cen-
ters delivered usual care. Randomization took place on
healthcare center level. The healthcare centers were classi-
fied in two classes: with high or low task delegation from
general practitioners to nurses. The healthcare centers in
the classes were then randomly allocated to the groups
(See: consort Figure 1).
A two-sided P value < 0.05 was used. Based on a two-
sided Type 1 error (α) = 0.05, with an 80% power to de-
tect a 25% relative reduction in quitting rates, allowing
20% loss during follow-up, we need that each group
should contain a minimum of 7 healthcare centers s and
at least 50 patients with COPD per group.
This study was approved by the Ethics Committee of
the Xuzhou Center for Disease Control and Prevention
and the Regional Ethical Vetting Board, Xuzhou, China.
In addition, agreement was received from all of the
relevant health centers. Informed consent was obtained
from all participants.
Subjects
Patients were recruited by their family physicians from
14 healthcare units in rural area of Xuzhou city, China,
from January to March 2008. Patients had to meet the
following criteria at baseline: COPD diagnosed by the
standards set forth by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) [22]. Which means
all participants underwent standard measurements of
lung function (post-bronchodilator forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) <70%)
by the County People’s Hospital. Reversibility of airways
obstruction was measured according to standard Amer-
ica Thoracic Society guidelines (over 15% and at least
400 ml improvement in FEV1 after 400 μg salbutamol
via a spacer) [23]. The study population consisted of
current smokers with all stage COPD. All patients were
aged 35 years or older, had smoked 1 cigarette or more
per day for the previous year, and had not stopped
smoking for more than 3 months during that year. We
excluded participants who had any serious or unstable
medical disorders such as psychiatric that might affectlung function or they had a current diagnosis of major
depression.
Participants were considered as loss to follow-up if
they could not contact, died, move to another place,
withdraw consent, refuse to proceed, invalid data, or un-
able to complete the study due to other reasons.
Behavioral interventions
During the screening phase, individuals selected a date to
stop smoking (target day) and were told not to attempt to
stop before this day. Patients were also told the aim of the
study.136 general practitioners, working at 7 different
healthcare centers of the intervention group, followed
6 hours training in behavioral interventions for quitting
smoking. The training included: ingredients of tobacco,
the potential harmful of smoking, smoking and COPD,
harmful of exposure to tobacco smoke, smoking's impact
on the economy, weigh the pros and cons of smoking and
smoking cessation, why the COPD patients need quit
smoke, benefits of quitting smoking, how to deal with
smoking cravings, how to preventing relapse smoking,
how to develop smoking cessation programs, how to help
them quit smoking and the motivational interview.
The teams of general practitioners (including assis-
tants and nurses) were established in the healthcare cen-
ters of intervention group. They were responsible for
supervising and advising patients with COPD registering
in their healthcare centers to quit smoke. The tasks of
them included home visiting patients with COPD at
least once a week, to obtain the current condition of
quitting smoking, tell the patients how to do next, and
record the time of quitting smoking. If a patient has
quitted smoking, the general practitioners were to
follow-up the patient once a week at the first month and
afterwards once a month until the end the study. Mean-
while, they also were responsible for examining the ex-
haled carbon monoxide (CO) level for COPD patients.
Every month, the participants were asked to meet to-
gether once to discuss relevant questions for quitting
smoking and share the experience of quitting smoking.
The professional group (including respiratory, rehabilita-
tion, nutrition, sports and psychology specialists) rou-
tinely visited the COPD patients in healthcare centers
every two months. The general practitioners in the
healthcare centers reported the follow-up status of pa-
tient with COPD and smoking cessation conditions once
a month. The professional group assessed smoking ces-
sation conditions, developed the focus of the next
follow-up period for each patient, and sent the focus to
the teams of the general practitioners. The focus was
how to improve patients’ quitting smoking during next
follow-up period. The professional group also provided
other physiological supporting, including the benefits of
smoking cessation and how to deal with obesity. This
Table 1 Baseline characteristics within healthcare units
Intervention group Control group
No of units 7 7
Population 301,785 298,467
Annual per capita income (Yuan) 21,345 ± 464 21,545 ± 471
Per capita housing area (m2) 25.6 ± 6.4 25.6 ± 6.5
medical staff 2,162 2,147
Medical staff constitute
Doctor 654 (38.1) 648 (37.0)
Nurse 1,041 (38.7) 1,058 (41.0)
Medical staff educational background
Undergraduate or above 1,576 1,573
Junior college 482 479
Medical staff professional titles
Senior title 559 855
Intermediate title 881 878
Figures are numbers (percentages) unless stated otherwise.
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personnel support was offered with easily access for all
participants. All participants were tested for exhaled car-
bon monoxide (CO) level at the baseline and every six
months in the follow-up period.
At the baseline, all patients were interviewed by the gen-
eral practitioners and the professional group at healthcare
centers. All participants were asked if they were willing to
quit smoking. The participants who would like to quit
smoking were given a booklet that included:
– how many harmful ingredients are in cigarettes;
– smoking and disease (included: COPD);
– Benefits of quitting smoking;
– how to deal with cravings for smoking;
– Ways to quit smoking.
For the patients in intervention group, we strongly en-
couraged them to stop smoking, and received brief smok-
ing cessation advice after the baseline interview, which
consist of 5–8 minutes’ discussion with member of profes-
sional group about their smoking habits. Smoking cessa-
tion advice was focused on the risk of developing COPD,
lung cancer, coronary artery disease, and the harmful ef-
fects to other family members. If the participants wanted
to stop smoking, we provided them a plan to quit smok-
ing. For example, we asked the participants to set date to
stop smoking (target day). If the patients currently smoked
twenty cigarettes per day, they could decrease two ciga-
rettes per day or two days. If the patients did not want to
stop smoking, we encouraged them to stop smoking
within six months. They could decrease one cigarette per
day or one week. It was suggested for all participants to
postpone the time as long as possible when they want to
smoke. Drinking water, talking with someone, or turning
their attention on other things were recommended as ef-
fective ways to postpone smoking time. No pharmaco-
logical treatment for smoking addiction was provided in
the current study.
Smoking status
An exhaled carbon monoxide (CO) measurement was
taken at baseline and every six month in the follow-up
period to confirm smoking status at healthcare centers.
The primary efficacy measure was continuous abstinence
from smoking for 2 years from the start of month 24 to
the end of month30. We defined continuous abstinence
as a participant report of zero cigarettes per day for at
least 6 months and confirmed by exhaled carbon mon-
oxide values of 10 parts per million
Secondary measures of efficacy were continuous absti-
nence during month 24–36 and 24–48. Continuous abstin-
ence for months 24–48 was defined by participants being
continuously abstinent during months 24–36, having adiary cigarette count of zero during weeks 37–48, and
having exhaled carbon monoxide values of 10 ppm or
less at month 48.
Assessment of influencing factors
All participates were asked to complete a questionnaires
that included age, sex, current employment status, educa-
tion level, marital status, physical activity, alcohol use,
number of smoking family member, number of cigarettes
smoked, motivation to stop smoking, smoking pack years
(average daily numbers of cigarettes smoked divided by 20
and multiplied by the smoking years). Comorbidities in-
cluding chronic bronchitis or emphysema, asthma, other
lung disease, diabetes, treatment for blood pressure,
stroke, coronary heart disease (angina or heart attack), or
other heart disease and conditions were recorded on pa-
tient’s baseline reports. Education was categorized into
below high school, high school, or above high school
levels. Alcohol drinking was defined as the consumption
of at least 30 g of alcohol per week for one or more
years. The height and weight were measured, and body
mass index (BMI) was calculated (BMI = weight in kilo-
grams divided by height in meters squared). BMI was
categorized as underweight (≤18.5 kg/m2), normal (18.5
to ≤24.0 kg/m2) or overweight/obese (≥24.0 kg/m2)
[24]. Mental health (depression and anxiety) was evalu-
ated by the Hospital Anxiety and Depression Scale
(HADS) [25]. Dyspnea was measured using the Medical
Research Council (MRC) dyspnea scale [26] and
FagerstrÖm Test for Nicotine Dependence (FTND) [27].
Usual care
Participants in control group were treated by healthcare
providers or general practitioners as usual manner. The







Men 868 (100) 840 (100)
Women 946 (100) 908 (100)
Age
40~ 292 (100) 279 (100)
50~ 370 (100) 358 (100)
60~ 507 (100) 490 (100)
70~ 478 (100) 463 (100)
80~ 167 (100) 158 (100)
Education level
High 159 (100) 152 (100)
Middle 327 (100) 323 (100)
Low 1328 (100) 1273 (100)
Household income
High 148 (100) 146 (100)
Middle 1529 (100) 1466 (100)
Low 137 (100) 136 (100)
Alcohol user
Yes 659 (100) 628 (100)
No 1155(100) 1120 (100)
Comorbidities
Yes 473 (100) 459 (100)
No 1341 (100) 1289 (100)
Depression
Yes 640 (100) 622 (100)
No 1174 (100) 1126 (100)
Anxiety
Yes 343 (100) 337 (100)
No 1471 (100) 1411 (100)
Pack years
<30 604 (100) 572 (100)
30~ 648 (100) 631 (100)
40~ 562 (100) 545 (100)
Nicotine addiction (FagerstrÖm score)
0~3 526 (100) 502 (100)
4~6 648 (100) 654 (100)
≥7 640 (100) 592 (100)
MRC scales
0 91 (100) 89 (100)
1 358 (100) 346 (100)
2 524 (100) 499 (100)
3 502 (100) 486 (100)
4 339 (100) 328 (100)
Table 2 The characteristics and smoking rates at
the baseline (Continued)
Smoking history of family members
Yes 1128 (100) 1075 (100)
No 686 (100) 673 (100)
Smoking history of the responsible doctor or nurse
Yes 798 (100) 778 (100)
No 1016 (100) 970 (100)
MRC Medical Research Council.
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standardized. Participants were follow-upped once every
2 months, and asked whether the symptoms aggravated,
what medication they used, etc.
Statistical analyses
We did all analyses on the intention-to-treat population,
which consisted of patients who took at least one month
of our study. All participants who withdrew from the
study were taken to be smokers thereafter.
SPSS for Windows version 11.5 (SPSS Inc.) was used
for data analysis. Tests were considered as significant
when P < 0.05. Baseline demographic and smoking char-
acteristics as well as mean scores of MRC, and mental
health were compared to assess potential differences be-
tween intervention group and control. T-test was used
to analyze the differences in mean scores between the
groups. A chi-squared test was used to evaluate the stat-
istical significance of smoking cessation rates between
the two groups. We studied the effect of age, sex, educa-
tion level, household income, alcohol user, depression,
anxiety, smoking pack-years, Nicotine addiction, dyspnea,
smoking history of family members and smoking history
of the responsible doctor or nurse of patients with multi-
variate logistic regression. These variables were added to
the basic model including intervention group assignment
and centre. Candidate variables (P < 0.05) were entered
into the multiple logistic regression models analysis to
analyze risk factors affecting quit smoking. Odds ratios
(OR), confidence intervals (CI) and p values were
calculated.
Results
General characteristics of the participants at the baseline
The two groups were drawn from a single district and
were similar in annual averaged income, access to health
services and main demography at baseline (Table 1).
Among 3562 smokers, 26.8% did not complete the
follow-up visit, i.e. 46 subjects had moved away from the
region, 39 declined to participate in the follow-up visit for
miscellaneous reasons, 20 did not complete exhaled car-
bon monoxide (CO) level test, 23 were incomplete data,
and 827 died (intervention: 370 vs control: 457; χ2 = 28.76,
Table 3 Abstinence rates during intervention and follow-
up phases
Month Continuous abstinence P
Intervention group Control group
(n = 1377) (n = 1230)
6 79(5.7%) 3(0.2%) <0.001
12 198(14.4%) 11(0.9%) <0.001
18 342(24.8%) 24(2.0%) <0.001
24 508(36.9%) 36(2.9%) <0.001
30 639(46.4%) 42(3.4%) <0.001
36 630(45.8%) 49(4.0%) <0.001
42 622(45.2%) 57(4.6%) <0.001
48 610(44.3%) 63(5.1%) <0.001
No cigarettes from month 6 onwards.
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tion and control group were 437 and 518, respectively.
Significant difference in lost rates was observed between
behavioral intervention and control group (χ2 = 13.94,
P < 0.001). There were no statistically significant diffe-
rences in the smoking history, age and sex between those
who attended the follow up and non-responders. Finally,
2607 subjects were analyzed in the study, 1377 in beha-
vioral intervention group and 1230 in control group
(Figure 1). In behavioral intervention group, the mean
ages, median smoking years, median nicotine dependence
scales and median MRC scales were 61.6 ± 10.2 years,
37.8 ± 11.7 pack-years, 5.1 ± 2.1 and 2.4 ± 1.5, res-
pectively. In the control group, the mean age of 61.5 ±
10.1 years, median smoking years of 37.6 ± 11.5 pack-
years, and median nicotine dependence scales of 5.0 ± 1.9.
No statistically significant differences in these indicators
were observed between the two groups. Other descriptive
characteristics for behavioral intervention and control
group were shown in Table 2. Which showed no statisti-
cally significant differences between the intervention and
control groups (all Ps > 0.05).
Quit smoking rates
The rates of continuous abstinence from month 24 to the
end of month 30 was higher in the intervention group
than that in the control group ( 46.4% vs 3.4% p < 0.001).
639 out of 1377 (46.4% ) participants receiving behavioral
intervention remained abstinent compared with 42 out
of 1230 (3.4%) receiving usual care. Rates of continuous
abstinence were significantly higher with behavioral
intervention than with usual care throughout the
24-month intervention phase and at the 48 month
follow-up visit (Table 3). At the 48 month follow-up,
more participants receiving behavioral intervention
remained abstinent than those receiving usual care
(44.3% vs 5.1% , p < 0.001). Behavioral intervention wassignificantly better than usual care at months 36–48
during the follow-up phase (p < 0.001).
The significant differences of continuous smoking absti-
nent rates were consistently observed for all subgroups
(such as different ages, gender, education levels, household
income, alcohol user and comorbidities etc.), i.e. higher
smoking cessation rate in intervention group than that in
control group (Table 4).
Verified quit smoking
The successful smoking cessation during the 4-year follow
up was confirmed by a low exhaled CO level for 610 sub-
jects. The mean exhaled CO in sustained quitters was sig-
nificantly lower (mean = 3.7 ppm, SD = 1.5) compared
with continuous smokers (mean = 15.7 ppm, SD = 5.1,
p < 0.001). Subjects who were continuous smokers also
reported a reduced cigarettes smoked per day at the end
of 4-year follow up (mean = 14.5, SD = 7.2) compared to
the baseline (mean = 20.5, SD = 9.2).
Risk factors affecting smoking cessation
Independent predictors of successful smoking cessation in-
cluded women, older age, no-drinkers, comorbidities,
lower HADS-anxiety (HADS-A), lower HADS -depression
(HADS-–D), less smoking pack years, lower FagerstrÖm
score, and higher MRC score (Table 5). Patients were more
likely to quit smoking if they had the family physicians/
nurses nonsmoking or no family member smoking
(Table 5). In other words, the family physicians/nurses
and family members smoking were two strong predic-
tors of failure to quit smoking. Other confounders
might also play a role. The multiple logistic regression
analysis showed significant effects for alcohol drinkers,
comorbidities, HADS-A, HADS-D, smoking pack years,
FagerstrÖm score, MRC score, family members smo-
king, and the family physicians/nurses smoking as pre-
dictors of smoking cessation by adjusting age and
gender (Table 5). The family members smoking was the
strongest predictor of sustained smoking (OR = 12.1).
Discussion
Our results show that the behavioral intervention group
had the high rate of abstinence from smoking over
24 months in smokers with COPD compared with the
control group. This advantage over usual care continued
for 24 months after discontinuation of the behavioral
intervention. It also shows that the family physicians/
nurses and family members smoking were two strong
predictors for failure to quit smoking.
Overall, the population-attributable risk of COPD re-
lated to cigarette smoking was higher (about 45%)[28,29].
Smoking cessation is an efficient way of slowing down
COPD progression. The Lung Health Study (LHS) exam-
ined the effects of tobacco intervention on COPD
Table 4 Observed frequencies of abstinence from month 31 to end of month 48
Variables Smoking cessation group (n= 1377) Control group (n= 1230) Difference (95% CI) P value
Sex
Men (%) 265/659 (40.2) 28/601 (4.7) 35.5 (23.6-49.8) P<0.001
Women 345/718 (48.0) 35/628 (5.6) 42.4 (27.8-58.6) P<0.001
Age
40~ 87/221 ( 39.4) 5/197 (2.5) 36.9 (29.5-45.6) P<0.001
50~ 118/280 (42.1) 11/250 (4.4) 37.7 (26.5-50.1) P<0.001
60~ 171/385 (44.4) 17/343 (5.0) 39.4 (26.6-53.4) P<0.001
70~ 167/362 (53.8) 17/323 (5.3) 48.5 (37.8-60.7) P<0.001
80~ 67/129 (51.9) 13/117 (11.1) 40.8 (33.5-49.2) P<0.001
Education level
High 74/143 (51.7) 8/129 (6.2) 45.5 (37.7-54.3) P<0.001
Middle 137/313 (43.8) 14/280 (5.1) 38.7 (25.4-53.2) P<0.001
Low 399/921 (43.3) 41/821 (5.0) 38.3 (20.6-57.3) P<0.001
Household income
High 48/112 (42.8) 7/114 (6.1) 36.7 (30.3-43.9) P<0.001
Middle 524/1173 (44.7) 53/1051 (5.0) 39.7 (20.5-59.8) P<0.001
Low 38/92 (41.2) 3/65 (4.6) 36.6 (31.3-42.4) P<0.001
Alcohol user
Yes 201/498 (40.4) 17/434 (3.9) 36.5 (25.6-49.4) P<0.001
No 409/879 (46.5) 46/796 (5.8) 40.7 (26.4-56.1) P<0.001
Comorbidities P<0.001
Yes 68/136 (50.0) 15/121 (12.4) 37.6 (25.3-55.4) P<0.001
No 542/1241 (43.4) 48/1109 (3.9) 39.5 (20.7-58.6) P<0.001
Depression
Yes 95/513/(18.5) 13/518 (2.5) 16.0 (12.7-20.5) P<0.001
No 515/864 (59.6) 50/712 (7.0) 52.6 (41.9-63.5) P<0.001
Anxiety P<0.001
Yes 81/258 (31.4) 9/230 (4.0) 27.4 (20.1-35.7) P<0.001
No 529/1119 (47.3) 54/1000 (5.4) 42.1(33.3-51.1) P<0.001
Pack years
<30 266/564 (47.2) 32/504 (6.3) 40.9 (32.4-50.4) P<0.001
30~ 200/454 (44.1) 18/406 (4.4) 39.7 (31.8-48.2) P<0.001
40~ 144/359 (40.1) 13/320 (4.1) 36.0(29.7-43.3) P<0.001
Nicotine addiction (FagerstrÖm score)
0~3 243/432 (56.3) 25/386 (6.5) 49.8 (35.6-64.6) P<0.001
4~6 233/486 (47.9) 23/434 (5.3) 42.6 (29.1-56.7) P<0.001
≥7 134/459 (29.2) 15/320 (4.7) 24.5 (13.4-36.6) P<0.001
MRC scales
0 21 /70(30.0) 2/71 (2.8) 27.2 (22.6-32.3) P<0.001
1 107/272 (39.3) 7/243 (2.9) 36.4 (27.5-46.3) P<0.001
2 175 /398 (44.0) 17/356 (4.8) 39.2 (27.7-51.7) P<0.001
3 178/380 (46.8) 20/339 (5.9) 40.9 (28.1-54.4) P<0.001
4 129/257 (50.2) 15/221 (6.8) 43.4 (31.1-56.7) P<0.001
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Table 4 Observed frequencies of abstinence from month 31 to end of month 48 (Continued)
Smoking history of family members
Yes 247/816 (30.3) 28/729 (3.8) 26.5 (13.2-40.1) P<0.001
No 363/561 (64.7) 37/501 (7.4) 57.3 (38.9-76.2) P<0.001
Smoking history of the responsible doctor or nurse
Yes 214/589 (36.3) 22/526 (4.2) 32.1 (21.7-43.9) P<0.001
No 396/788 (50.3) 41/704 (5.8) 44.5 (32.1-57.6) P<0.001
Table 5 Multiple logistic regression analyses for factors
associated with failure smoking cessation


















30~ 1.08 1.01-1.24 0.009
40~ 1.55 1.34-2.21 0.000
Nicotine addiction (FagerstrÖm score)
0~3 1.00
4~6 1.25 1.09-1.49 0.002
≥7 1.62 1.29-2.15 0.000
MRC scales
4 1.00
3 1.37 1.12-1.66 0.001
2 1.52 1.28-1.81 0.000
1 1.65 1.35-2.01 0.000







MRC Medical Research Council.
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mild to moderate COPD were followed up at 4-month in-
tervals to check on smoking status and the compliance
with smoking cessation determined by self-report and
verified by measuring expired carbon monoxide and sali-
vary cotinine levels. Over the 4 years of follow-up, 22% of
patients with COPD were continuous abstinence smokers
in two groups receiving special tobacco treatment. In con-
trast, only 5% of the patients in usual care group became
continuous abstinence smokers. Smoking habits by ori-
ginal Lung Health Study treatment groups tended to con-
verge, but 93% of participants who were abstinent
throughout the Lung Health Study were still abstinent at
11 years [30]. Our behavioral intervention showed a con-
sistent and significantly higher continuous smoking abstin-
ence rate (44.3%) in patients with COPD compared with
control group (5.7%) after four years. We also found that
22.6% of smokers reduced the amount of cigarettes
smoked. These data highlighted the feasibility and efficacy
to conduct community-based smoking cessation in patients
with COPD. The long term follow-up studies are warrant
to evaluate the longitudinal effects of smoking cessation.
Our study also identified several important factors which
potentially impact smoking cessation, including women,
older, non-drinkers, comorbidities and dyspnea. Patients
with depression, anxiety, higher smoking pack years and
nicotine addiction were difficult to quit smoking. These
results provided additional information and potential
methods to improve the management of COPD patients.
For example, a previous study found that female smokers
with COPD might experience a faster decline in lung func-
tion than male smokers [31]. Another study indicated that
female smokers had larger gains in lung function when
stopped smoking compared with male quitters [32]. These
data strongly suggested that smoking cessation was par-
ticularly important for women because they had increased
susceptibility to COPD progression if continued smoking,
but may obtain more benefits if quitting smoking com-
pared with male smokers. These results could be used as
strong biological evidence and tools in conducting
community-based intervention to convince women quit
smoking. It was also consistent with our observational
study that women with COPD were relatively easy to quit
smoking.
Lou et al. BMC Family Practice 2013, 14:91 Page 9 of 10
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members smoking and family physicians smoking) were sig-
nificantly associated with smoking cessation in China. Luker
conducted a systematic review to assess the effectiveness of
family-focused smoking cessation interventions for patients
with COPD [33]. However, no conclusion was obtained
about the effectiveness of a family-focused intervention, in-
cluding factors of marital status, smoking status of house-
hold members and support for smoking cessation. The
negative impact of smoked doctors or nurses on smoking
cessation of COPD patients displayed a great challenge we
faced on community-based intervention. The doctors or
nurses usually provided a positive attitude and health know-
ledge to persuade COPD patients to quit smoking, which
played a critical role in improving the efficacy of smoking
cessation intervention. The message that “quitting smoking
benefits your health or disease progression” may not be
convincible if provided by doctors or nurses who are
smokers. On the other hand, our data also suggested that
there is a lot of space to improve the smoking cessation if
we can firstly persuade the doctor or nurse to quit smoking.
The strengths of current study included a community-
based intervention design, large sample size, randomly se-
lected intervention and control groups, and low rate of
loss of follow-up. The accurate smoking cessation data
obtained by both questionnaires and exhaled CO meas-
urement also made the current results more reliable. One
limitation was a moderate duration (four years) that could
not evaluate the long-term efficacy of smoking cessation.
No detailed data on comparison lung functions and other
clinical outcomes of COPD patients before and after
smoking cessation is also limited, which may potentially
reduce the efficacy of quitting smoking. Previous studies
have demonstrated that smoking cessation was associated
with a slower decline in lung function and reduced risk of
hospitalization and total mortality in another study [8].
Knowing smokers’ lung function being declining might
help motivate patients to quit smoking [18,34,35]. This
data strongly encouraged us to adopt lung function detec-
tion in the community-based intervention to improve the
efficacy of smoking cessation.
Conclusions
In summary, our community-based study revealed two-
year behavior intervention significantly decreased smok-
ing rate in currently smoked patients with COPD.
Several important factors have been identified to posi-
tively or negatively impact smoking cessation, especially
the smoking behaviors of other family members and the
responsible doctors or nurses that were first associated
with smoking cessation. Long-term follow-up for smoked
patients with COPD and validating their lung functions
may further improve the effect of community-based inter-
vention, and benefit the prognosis of COPD patients.Competing interests
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